BNET Industries
Market Cap:$14.6B
Last Fiscal Year Sales:$15.6B
- Public
- NL
Dow Jones Description
Akzo Nobel's paint colors turn the competition green. Founded in 1911 and headquartered in Arnhem, Netherlands, Akzo Nobel N.V. (NASDAQ: AKZOY (ADR); AMS: AKZA) is the world's largest paint maker, among other businesses. The company operates in several segments. Coatings segment produces paints, stains, chemicals, auto finishes, and synthetic resins. Pharmaceuticals segment produces prescription and over-the-counter drugs. Chemicals segment produces specialty, functional, and commodity chemicals. The company has annual revenue of about ?13 billion and employs about 61,500 people. Akzo Nobel was listed on FTSE4Good Index in 2006. In 2005 it was selected as a member of the prestigious Dow Jones Sustainability Indexes, World and Stoxx.
Chairman & CEO
G.J. WijersNumber of Employees 42,600
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
Recent Events
-
2nd UPDATE: Akzo 3Q Net Profit Up, Fiscal Year Outlook Missing
-
UPDATE: AkzoNobel 3Q Net Profit Up 30%, No Full-Year Outlook Given
-
Kemira to buy Akzo Nobel's iron coagulant business in Nordic countries
-
BRIEF-RESEARCH ALERT-Goldman cuts Givaudan to sell; raises Syngenta, DSM to buy
-
Akzo profit a sign chemical makers have potential to surprise
-
2nd UPDATE: AkzoNobel 2Q Net 13% Down, No Fiscal Year Outlook Given
-
Akzo Nobel reports 13% decline in 2Q net income to Euro 155 million for 2009
News & Analysis
Filter by
akzo nobel n.v. and organon inc. - All News and Analysis
… And admits "Oil for Food" blunder
- 2008-01-14
Akzo Nobel signed a non-prosecution agreement with the US Department of Justice in late December acknowledging responsibility for the actions of two of its former subsidiaries, Organon and Intervet International. Employees, and representatives of these companies are said to have made improper payments to the Iraqi government between 2000 and...
Schering-Plough has completed its acquisition of Organon Bioesciences
- 2007-12-04
Schering-Plough has completed its acquisition of Organon Bioesciences from Akzo Nobel for 11bn [euro].
Organon, Akzo Nobel's healthcare business, has agreed with US biopharmaceuticals developer Dyax to jointly discover and develop therapeutic antibodies for treating auto-immune diseases and cancer
- 2007-07-30
Organon, Akzo Nobel's healthcare business, has agreed with US biopharmaceuticals developer Dyax to jointly discover and develop therapeutic antibodies for treating auto-immune diseases and cancer. Dyax will use its phage display technology to identify antibodies directed towards a target identified by Organon's research centre in Cambridge, Massachusetts, US.
Netherlands-based Akzo Nobel, owner of Diosynth Biotechnology of Research Triangle park and other pharmaceutical operations known as Organon Biosciences
- 2007-07-01
Netherlands-based Akzo Nobel, owner of Diosynth Biotechnology of Research Triangle park and other pharmaceutical operations known as Organon Biosciences, has announced plans to sell the operations to Schering-Plough of Kenilworth, N.J., for $14.4 billion. Diosynth, a contract biomanufacturer, employs about 500 people in the Research Triangle area.
Dutch healthcare subsidiary of Akzo Nobel, Organon has entered into a collaborative agreement with US biopharma concern Medarex
- 2007-05-28
Dutch healthcare subsidiary of Akzo Nobel, Organon has entered into a collaborative agreement with US biopharma concern Medarex to develop and potentially commercialise fully human antibody therapeutics for the treatment of cancer and auto-immune diseases, using Medarex's UltiMAb human antibody development system.
Dutch chemicals firm Akzo Nobel has reported a 1% revenue increase for chemicals and coatings in Q1 2007 to reach 2.5bn [euro]
- 2007-05-07
Dutch chemicals firm Akzo Nobel has reported a 1% revenue increase for chemicals and coatings in Q1 2007 to reach 2.5bn [euro]. Following the sale of Organon Biosciences, the company's pharma activities are reported as discontinued activities. Net income from Organon in Q1 was up 9% at 111m [euro], ...
ICI bid rumoured
- 2007-04-23
Rumours of a bid for former UK chemical industry bellwether ICI continue. UK newspaper The Independent reported that Dow Chemical might be preparing a 610p/share offer for the speciality chemicals and paints business. Akzo Nobel was previously linked to a bid for ICI after the sale of Organon Biosciences left...
Akzo Nobel intends to sell Organon BioSciences to Schering-Plough.(NEWSDESK: Business)
- 2007-03-26
Akzo Nobel is pleased to announce that on March 11th, 2007, it received an offer for the purchase of its wholly owned subsidiary Organon BioSciences N.V. OBS from Schering-Plough for EUR 11 billion in cash. As a result, Akzo Nobel will no longer be proceeding with the...
Schering-Plough set to acquire Organon
- 2007-03-26
US drug firm Schering-Plough is to acquire Organon BioScences, the human and animal healthcare businesses of Dutch chemical/ healthcare group Akzo Nobel, for about $14.4bn in cash, around a 35% premium. Although there is little therapeutic overlap between the two companies, the deal will push Schering-Plough from 17th to...
ICI back in takeover spotlight as Akzo builds [euro]11bn war chest
- 2007-03-13
The Dutch healthcare and chemicals group Akzo Nobel ditched plans to float its biopharmaceutical division in favour of a sale yesterday, triggering speculation it would next make a move on the chemicals group Imperial Chemical Industries. Shares in ICI, the UK's largest speciality chemicals maker, jumped 5.5...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| R.J. Frohn | CFO |
| Rob Frohn | CFO |
| Keith Nichols | Senior Vice President, Finance |
| O. Werner | Senior Vice President, HR |
| Jan H. Dopper | Technology Director |
| John McLaren | Director, Corp Communications |
| M. Rooseboom | Senior Group Director, Coatings |
| Barry Oonk | Manager, Advertising |
| Bill McPherson | General Manager, Marine & Protective Coatings |
| Rob Molenaar | General Manager, Powder Coatings Business |
| A. Jan Eijsbouts | General Counsel |
| A.T.M. Wilderbeek | Member, Management Bd, Pharma |
| Han Jalink | Secretary |
| Leif Darner | Head |
| Rudy M.J. van der Meer | Member, Management Bd, Coatings |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| G.J. Wijers | Chairman & CEO |
| Antony Burgmans | Supervisory Board |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Chairman & CEO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Technology Director | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Director, Corp Communications | Current |
| Akzo Nobel N.V. | Director, Corp Communications | Former |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Group Director, Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Manager, Advertising | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Marine & Protective Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Powder Coatings Business | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Counsel | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Pharma | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Head | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Coatings | Current |
| James Hardie Industries N.V. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Amoco Ultimate | Board of Directors | Current |
| Bp Alternative Energy | Board of Directors | Current |
| Air Bp Limited | Board of Directors | Current |
| Bp Refining and Petrochemical | Board of Directors | Current |
| Progas Limited | Board of Directors | Current |
| The Bp Group | Board of Directors | Current |
| Bp Solar Neighbors Program | Board of Directors | Current |
| Akzo Nobel N.V. | Supervisory Board | Current |
| Bp Solar International, Inc. | Board of Directors | Current |
| Bp Marine | Board of Directors | Current |
| AEGON N.V. | Supervisory Board | Current |
| BP plc | Board of Directors | Current |
| Wristore | Board of Directors | Current |
| Unilever N.V. | Business Group Vice President | Former |
| Unilever | Marketing Assistant | Former |
| Unilever N.V. | Chairman, Unilever Indonesia | Former |
| Unilever N.V. | Chairman | Former |
| Unilever N.V. | Vice Chairman | Former |
| Unilever Plc | Vice Chairman | Former |
| Unilever | Board of Directors | Former |
| University of Lancaster | MA | Former |
| Nijenrode University | Former | |
| University of Stockholm | Former |
| Volume | 11,474 |
| Shares Outstanding | 231.6M |
| Market Cap | 14.6B |
| Year High | 70.00 |
| Year Low | 32.15 |
| Earnings Per Share | -6.7840 |
| P/E Ratio | N/A |
| Dividend | 1.94 |
| Yield | 3.0698 |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express